ROCHESTER, N.Y. & LEXINGTON, Mass.-(BUSINESS WIRE)-MC10, Inc., creators of the innovative wearable device BioStamp nPoint, and the University of Rochester announced today a collaboration on advancing methods of assessing Central Nervous System diseases.
The collaboration will utilize the BioStamp nPoint system to collect continuous data allowing for the creation of algorithms to provide quantitative assessment of disease progression, specifically for movement disorders.
“Movement disorders such as Huntington’s and Parkinson’s disease represent a therapeutic area that lacks objective, quantitative understanding of disease progression, and therapeutic efficacy. The goals of this research collaboration are to enhance the way we assess people with CNS diseases, improve the way therapies are evaluated, and transform the way these patients are managed toward better outcomes,” said Dr. Arthur Combs, MD, Chief Medical Officer of MC10. MC10 and the University of Rochester have a strong history of collaborations focused mainly on Central Nervous System developments, including prior studies on Parkinson’s and Huntington’s Disease patients.
“Neurological disorders are the world’s leading source of disability. Unfortunately, drug development for these disorders is littered with failures in part because of shortcomings in traditional rating scales. We need more objective, continuous, sensitive, real-world assessments of how these disorders affect individuals than we can get from subjective rating scales. Wearable sensors, like those from MC10, have the potential to provide us such data. Data that we can use to determine whether new therapies are efficacious,” said Dr. Ray Dorsey, a professor of neurology and director of the Center for Health Technology at University of Rochester.
The University of Rochester was recently named a Morris K. Udall Center of Excellence for Parkinson’s research and awarded a grant to work towards understanding the disease progression of the debilitating disease.